Semler Scientific

What Semler Scientific does

Semler Scientific, Inc. is a US-based medical technology company founded in 2007 and headquartered in Campbell, California. The company designs, manufactures, and markets QuantaFlo, an FDA 510(k)-cleared point-of-care device that uses infrared sensor-based volume plethysmography to measure arterial blood flow and detect Peripheral Arterial Disease (PAD) in under three minutes, including in patients with calcified vessels where conventional ABI testing fails. The core hardware is supported by a software ecosystem comprising SemlerShield (authentication), SemlerVault (secure data storage), SemlerAnalytics (clinical/operational/financial analytics), SemlerConnect (data workflow integration), SemlerHub (administrative data management), and a mobile SMS sync application. Semler primarily serves US healthcare providers — vascular specialists, primary care physicians, hospitals, clinics, and podiatrists — via a direct enterprise field sales motion, and also operates a wholly-owned SaaS subsidiary (CardioVanta, formed June 2025) focused on heart failure and cardiac arrhythmia monitoring.

The company monetizes through hardware sales of QuantaFlo sensors paired with recurring software subscriptions and cloud services, while also pursuing an unconventional Bitcoin treasury strategy (3,808 BTC with $387.9M fair value as of Q1 2025) funded by convertible notes and equity offerings. In January 2026, Semler Scientific was acquired by Strive, Inc. in a $1.34 billion all-stock transaction (21.05 Strive shares per Semler share), becoming a wholly-owned subsidiary of Strive and delisting from Nasdaq. The company had previously been subject to a $29.8 million DOJ civil settlement tied to False Claims Act violations involving medically unnecessary testing and fraudulent Medicare billing. Operational revenue is not explicitly disclosed, but capital-raising cadence and the scale of the DOJ settlement imply a mid-eight-figure revenue base.

Name

Semler Scientific

Legal name

Semler Scientific, Inc.

Website

https://semlerscientific.com

Company type

Public

Founded year

2007

Operating status

Acquired

Headcount range

51–100 employees

Short description

Semler Scientific is a US medical technology company that manufactures and sells QuantaFlo, an FDA-cleared point-of-care device for early detection of Peripheral Arterial Disease, serving healthcare providers through direct enterprise sales.

Ownership category

akta.pro rank

Product category

Vascular Diagnostics Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Cardiology Telemedicine Platforms (HLALAGAB)

Keywords

• Medical device manufacturing
• Vascular diagnostic equipment
• Point-of-care testing
• Peripheral arterial disease detection
• Cardiovascular diagnostics software

Headquarters

HQ city

Campbell

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. QuantaFlo Product Sales: Sale of QuantaFlo sensors and associated hardware for PAD testing. Sensors are compatible with a range of devices and patients including those with calcified arteries.
2. Software Subscriptions and Services: Revenue from software products including SemlerAnalytics (three-tiered analytics packages), SemlerConnect (data flow efficiency), SemlerHub (data management), SemlerShield (authentication), and SemlerVault (secure data storage). Also includes QuantaFlo SMS Sync mobile messaging service.
3. Bitcoin Treasury Operations: The company previously adopted Bitcoin as a treasury reserve asset, accumulating 3,808 BTC with fair value of $387.9 million as of Q1 2025. This was part of a strategic shift combined with its medical technology business.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Semler Scientific manufactures and sells the FDA-cleared QuantaFlo point-of-care medical device, which uses infrared sensor-based volume plethysmography to measure arterial blood flow in extremities and detect Peripheral Arterial Disease (PAD) in under three minutes, including in patients with non-compressible calcified arteries. The QuantaFlo platform is paired with a recurring software subscription suite (SemlerShield authentication, SemlerVault secure storage, SemlerAnalytics, SemlerConnect, SemlerHub), a mobile sync app, and the CardioVanta subsidiary focused on heart failure and cardiac arrhythmia monitoring.

Product overview

Semler Scientific offers a unified medical device platform centered on QuantaFlo, an FDA-cleared point-of-care product for early detection of Peripheral Arterial Disease (PAD). The core QuantaFlo system is supported by a suite of integrated software services: SemlerShield (authentication), SemlerVault (secure data storage), SemlerAnalytics (clinical/operational/financial analytics), SemlerConnect (data workflow integration), and SemlerHub (administrative data management). The company also offers a mobile sync application (QuantaFlo Sync) and maintains a training program (SemlerSimulation). In June 2025, the company launched CardioVanta, a subsidiary focused on heart failure and cardiac arrhythmia monitoring via SaaS. Legacy product FloChec was the company's first FDA-cleared PAD system (2010). The product portfolio spans medical devices, cloud software, mobile applications, and analytics—focused on early chronic disease detection at the point of care.

Differentiator

Problem solved

Functional benefit

Brands

• QuantaFlo: FDA-cleared point-of-care product that measures arterial blood flow in the extremities for early detection of Peripheral Arterial Disease (PAD)
• QuantaFlo PAD
• SemlerConnect
• SemlerHub
• SemlerShield
• SemlerVault
• SemlerAnalytics
• SemlerSimulation
• CardioVanta

Products and services

• QuantaFlo FDA-cleared point-of-care medical device that uses an infrared sensor to measure arterial blood flow fluctuations in extremities via volume plethysmography for early detection of Peripheral Arterial Disease (PAD). Delivers results in under 3 minutes and works in patients with calcified vessels where traditional ABI testing fails. Runs on Windows, Android, and iOS and integrates with EMR systems; sold to physicians, hospitals, clinics, podiatrists, and vascular specialists.
• QuantaFlo Sync (SMS Sync) Mobile messaging application enabling offline synchronization of QuantaFlo sensors by allowing users to send sensor sync codes via SMS to complete data transfers, supporting field and remote clinical use.
• FloChec First FDA 510(k)-cleared peripheral arterial disease testing system developed by Semler Scientific in 2010, predecessor to QuantaFlo.
• SemlerSimulation ANAB-accredited online training and certificate program for QuantaFlo users, providing standardized clinical and operational training on PAD testing workflows.
• CardioVanta Wholly-owned subsidiary of Semler Scientific structured as a SaaS business focused on early detection of heart failure and cardiac arrhythmia monitoring, targeting the $30 billion U.S. heart failure market affecting over 6 million Americans.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Partnerships

One partnership is on record.

• CardioVantacoreStrategic or Co-development Partner · 24 June 2025Semler Scientific formed CardioVanta, Inc. as a wholly-owned subsidiary focused on early detection of heart failure and cardiac arrhythmia monitoring. Structured as a SaaS business model seeking capital from outside investors, CardioVanta positions the company in the $30 billion heart failure market while maintaining the company's dual-force strategy in Bitcoin and medical technology.

Scale indicators7 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• AtCor Medical (CardieX / ATCOR subsidiary): CardieX (parent of ATCOR) develops SphygmoCor central blood pressure and arterial stiffness assessment technology. Both companies target non-invasive cardiovascular diagnostics at the point of care, with overlapping focus on PAD detection and vascular health.
• Itamar Medical (now part of ZOLL Itamar): Itamar Medical's WatchPAT and EndoPAT systems provide non-invasive cardiovascular diagnostics, including peripheral arterial tone assessment for sleep apnea and endothelial function. Directly comparable to QuantaFlo in point-of-care, non-invasive vascular diagnostics.
• Hokanson (D.E. Hokanson, Inc.): Hokanson is a long-standing provider of non-invasive vascular diagnostic instruments, including the gold-standard Doppler-based ABI systems used to diagnose PAD. A direct functional competitor to QuantaFlo's point-of-care PAD detection.

Emerging players

• Biobeat: Biobeat offers remote patient monitoring devices that measure multiple vital signs (BP, SpO2, heart rate, temperature) using a single chest patch or wrist-worn sensor. Comparable to Semler's QuantaFlo as a non-invasive, point-of-care cardiovascular/vital sign monitoring tool targeting chronic disease management.
• VitalConnect: VitalConnect provides wearable biosensor patches for continuous vital sign monitoring in hospital and remote settings. Comparable to Semler in delivering FDA-cleared, point-of-care cardiovascular monitoring data with cloud connectivity.
• iRhythm Technologies: iRhythm's Zio cardiac monitoring patch provides continuous, ambulatory cardiac arrhythmia detection via a single-use wearable. Relevant CardioVanta peer given the SaaS-driven cardiac arrhythmia monitoring overlap and similar remote monitoring business model.

Broad incumbents

• Philips (Philips Healthcare): Philips is a global incumbent in patient monitoring, diagnostic imaging, and cardiovascular care, offering ABI systems, vascular ultrasound, and integrated EMR-connected monitoring suites. Overlaps Semler in non-invasive PAD/vascular diagnostics as part of a much broader portfolio.
• GE HealthCare: GE HealthCare provides a broad portfolio of patient monitoring, cardiac diagnostics, and vascular assessment systems (including MAC, Dinamap, and ultrasound-based PAD workflows). A large incumbent competing with Semler in clinical cardiovascular diagnostics and hospital-based vital sign monitoring.
• Medtronic (Cardiac Diagnostics & Services): Medtronic operates cardiac diagnostic and remote monitoring businesses (including the LINQ ICM insertable cardiac monitor and CareLink network). Overlaps CardioVanta's cardiac arrhythmia monitoring ambition and competes broadly in cardiovascular diagnostics.
• Preventice Solutions (Boston Scientific): Boston Scientific's Preventice BodyGuardian remote cardiac monitoring system provides ambulatory ECG and arrhythmia detection via wearable sensors and a cloud platform. A direct comparable to CardioVanta's SaaS-based cardiac monitoring model under a much larger parent.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/wixstudio
• Xx.com/SemlerSci
• LinkedInlinkedin.com/company/semler-scientific

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Semler Scientific